MicroRNA-based Targeted Therapeutics in Pancreatic Cancer

GÜRBÜZ N., Ozpolat B.

ANTICANCER RESEARCH, vol.39, no.2, pp.529-532, 2019 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 39 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.21873/anticanres.13144
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.529-532


The discovery during the last decade of microRNAs (miRs, miRNA) and their role in regulating normal physiological processes as well as in the pathogenesis of human tumors has been a revolutionary development in molecular oncology. miRNAs activating or inhibiting oncogenic molecular pathways that are involved in tumorigenesis, cell progression, invasion, angiogenesis and metastasis are now considered of major impact in many cancer types. miRNA-based therapeutics that inhibit the levels of oncogenic miRNAs (oncomiRs) or elevate tumor suppressor miRs have enormous potential as molecular therapeutic targets. Thus, the development of new targeted cancer therapies based on miRNAs promise to revolutionize cancer treatment due to their increased efficacy compared to conventional chemoradiation-based therapies and hopefully to lower levels of adverse effects.